Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization

View ORCID ProfileJean-François Rossignol, C. Bardin Matthew, Joshua B. Oaks, B. Gregory Bostick, Kishor N. Vora, Jessica Fulgencio, Dena Mogelnicki, View ORCID ProfileChristian Bréchot, Vanguard Study Group
doi: https://doi.org/10.1101/2021.04.19.21255441
Jean-François Rossignol
1Romark Institute of Medical Research, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jean-François Rossignol
C. Bardin Matthew
1Romark Institute of Medical Research, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: matthew.bardin@romark.com
Joshua B. Oaks
2Progressive Clinical Research, Bountiful, Utah
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
B. Gregory Bostick
3Cullman Clinical Trials, Cullman, Alabama
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kishor N. Vora
4Research Integrity, LLC, Owensboro, Kentucky
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jessica Fulgencio
1Romark Institute of Medical Research, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dena Mogelnicki
1Romark Institute of Medical Research, Tampa, Florida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Bréchot
1Romark Institute of Medical Research, Tampa, Florida
5University of South Florida, College of Medicine, Tampa, Florida
6Global Virus Network
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christian Bréchot
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Article usage

Article usage: April 2021 to March 2023

AbstractFullPdf
Apr 202157372401107
May 20211971124514
Jun 202193143190
Jul 202164853188
Aug 2021197095200
Sep 20211321100213
Oct 202194240157
Nov 2021856117161
Dec 2021108278195
Jan 202281137144
Feb 20223342562
Mar 20222434552
Apr 20222661757
May 20222592753
Jun 202219816105
Jul 20221316296
Aug 20221012352
Sep 2022851939
Oct 20221073438
Nov 2022872348
Dec 2022871237
Jan 2023641338
Feb 2023601231
Mar 2023432521
Back to top
PreviousNext
Posted July 17, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Jean-François Rossignol, C. Bardin Matthew, Joshua B. Oaks, B. Gregory Bostick, Kishor N. Vora, Jessica Fulgencio, Dena Mogelnicki, Christian Bréchot, Vanguard Study Group
medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization
Jean-François Rossignol, C. Bardin Matthew, Joshua B. Oaks, B. Gregory Bostick, Kishor N. Vora, Jessica Fulgencio, Dena Mogelnicki, Christian Bréchot, Vanguard Study Group
medRxiv 2021.04.19.21255441; doi: https://doi.org/10.1101/2021.04.19.21255441

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1254)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (537)
  • Epidemiology (10042)
  • Forensic Medicine (5)
  • Gastroenterology (500)
  • Genetic and Genomic Medicine (2473)
  • Geriatric Medicine (239)
  • Health Economics (482)
  • Health Informatics (1649)
  • Health Policy (756)
  • Health Systems and Quality Improvement (637)
  • Hematology (250)
  • HIV/AIDS (536)
  • Infectious Diseases (except HIV/AIDS) (11882)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2298)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1255)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (736)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2290)
  • Public and Global Health (4849)
  • Radiology and Imaging (844)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (654)
  • Rheumatology (288)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (227)
  • Surgery (271)
  • Toxicology (44)
  • Transplantation (130)
  • Urology (100)